After a rocky start to 2020, consumer DNA testing company 23andMe will close out the year with $82.5 million in new funding. The round was reported in a filing with the Securities and Exchange Commission last week, as first noted by the Silicon Valley Business Journal.
Sequoia Capital and NewView Capital led the raise, a company spokesperson wrote in an email. They said it was an extension of a previous $250 million series F round led by Sequoia.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Slowing demand for at-home DNA testing hit both 23andMe and its competitors earlier this year. In January, the company announced planned layoffs of 100 people, about 14% of its workforce.
A month later, Ancestry also cut 100 people, or roughly 6% of its workforce, citing a slowdown in demand across the category. Private equity firm Blackstone has since acquired it for $4.7 billion.
23andMe is still focused on consumer testing, research and drug discovery. Earlier this year, the company launched a study to identify genetic differences in patients that experience severe symptoms from Covid-19.
Participants submit survey answers and genetic data, which is de-identified and shared at the individual level with researchers. More than a million people have participated, including 15,000 that had tested positive for Covid-19 and 1,100 suffering symptoms that required hospitalization.